ArticleThrombosis research2022
Four cases of acquired hemophilia A following immunization with mRNA BNT162b2 SARS-CoV-2 vaccine.
Article in Thrombosis research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Acquired hemophilia A following SARS-CoV-2 infection and vaccination: clinical summary and insights.Journal of thrombosis and haemostasis : JTH · 2026Pooled it
- Acquired Hemophilia A after SARS-CoV-2 Immunization: A Narrative Review of a Rare Side Effect.Vaccines · 2024Review
- Hematological Complications in a COVID-19 Patient: A Case Report.Diseases (Basel, Switzerland) · 2023Article
- The role of emicizumab in acquired hemophilia A.Hematology. American Society of Hematology. Education Program · 2023Article
- Article
- Acquired hemophilia A following COVID-19 vaccine: a case report.Journal of medical case reports · 2023Article
- Hematological Questions in Personalized Management of COVID-19 Vaccination.Journal of personalized medicine · 2023Review
- Acquired Hemophilia A: An Update on the Etiopathogenesis, Diagnosis, and Treatment.Diagnostics (Basel, Switzerland) · 2023Review
- Acute-type acquired hemophilia A after COVID-19 mRNA vaccine administration: A new disease entity?Journal of autoimmunity · 2022Article
- Acquired hemophilia A secondary to SARS-CoV-2 pneumonia: a case report.Biochemia medica · 2022Article
- Acquired hemophilia following COVID-19 vaccination: Case report and review of literature.Research and practice in thrombosis and haemostasis · 2022Article
- Acquired Hemophilia A: A possibly fatal complication of SARS-COV-2 infection.Annals of medicine and surgery (2012) · 2022Article
- Case Report: Acquired Haemophilia A Following mRNA-1273 Booster Vaccination Against SARS-CoV-2 With Concurrent Diagnosis of Pleomorphic Dermal Sarcoma.Frontiers in immunology · 2022Article
- Acquired hemophilia A after vaccination against SARS-CoV-2 with the mRNA-1273 (Moderna) vaccine.Proceedings (Baylor University. Medical Center) · 2022Article
- Article
- Immune thrombocytopenic purpura following mRNA.Revista CuidarteArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acquired hemophilia A (AHA) is a rare autoimmune disease caused by neutralizing autoantibodies against coagulation Factor VIII. Immunomodulatory effects of SARS-CoV-2 vaccination are still poorly understood, with reports of immune-mediated conditions developing after immunization. In the province of Reggio Emilia, Northern Italy, we observed four cases of AHA following SARS-CoV-2 immunization with mRNA BNT162b2 vaccine (produced by Pfizer-BioNTech) during the first eight months from the beginning of SARS-CoV-2 vaccination campaign. During this time frame, 235,597 people received at least one dose of BNT162b2 vaccine. The total population of Reggio Emilia province is 526,349. The unusual observation of four cases of AHA in our province could be of interest and could sensitize healthcare personnel toward a possible complication of SARS-Cov-2 immunization. Nonetheless, vaccination benefits exceed potential side effects and play a central role in individual and public health to effectively protect people from COVID-19 and to stop the pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.